X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 44.5 25.6 173.4% View Chart
P/BV x 11.1 3.7 296.5% View Chart
Dividend Yield % 0.6 0.6 98.5%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
SUN PHARMA
Mar-17
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,015842 714.3%   
Low Rs3,707572 647.6%   
Sales per share (Unadj.) Rs1,236.9131.6 939.8%  
Earnings per share (Unadj.) Rs122.232.7 373.6%  
Cash flow per share (Unadj.) Rs129.038.0 339.6%  
Dividends per share (Unadj.) Rs35.003.50 1,000.0%  
Dividend yield (eoy) %0.70.5 145.5%  
Book value per share (Unadj.) Rs521.2152.7 341.3%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.95.4 73.1%   
Avg P/E ratio x39.821.6 184.0%  
P/CF ratio (eoy) x37.718.6 202.4%  
Price / Book Value ratio x9.34.6 201.4%  
Dividend payout %28.610.7 267.7%   
Avg Mkt Cap Rs m103,2961,696,877 6.1%   
No. of employees `0003.017.5 16.9%   
Total wages/salary Rs m3,37049,023 6.9%   
Avg. sales/employee Rs Th8,891.818,028.3 49.3%   
Avg. wages/employee Rs Th1,140.02,798.8 40.7%   
Avg. net profit/employee Rs Th878.34,479.5 19.6%   
INCOME DATA
Net Sales Rs m26,284315,784 8.3%  
Other income Rs m5046,232 8.1%   
Total revenues Rs m26,789322,016 8.3%   
Gross profit Rs m3,665100,893 3.6%  
Depreciation Rs m14412,648 1.1%   
Interest Rs m83,998 0.2%   
Profit before tax Rs m4,01790,479 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,42112,116 11.7%   
Profit after tax Rs m2,59678,462 3.3%  
Gross profit margin %13.931.9 43.6%  
Effective tax rate %35.413.4 264.2%   
Net profit margin %9.924.8 39.8%  
BALANCE SHEET DATA
Current assets Rs m14,446329,537 4.4%   
Current liabilities Rs m4,725178,870 2.6%   
Net working cap to sales %37.047.7 77.5%  
Current ratio x3.11.8 166.0%  
Inventory Days Days5179 65.1%  
Debtors Days Days2083 23.5%  
Net fixed assets Rs m1,113204,766 0.5%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m10,808363,997 3.0%   
Net worth Rs m11,076366,397 3.0%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m16,241614,102 2.6%  
Interest coverage x497.023.6 2,103.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.60.5 314.7%   
Return on assets %16.013.4 119.4%  
Return on equity %23.421.4 109.5%  
Return on capital %36.324.8 146.3%  
Exports to sales %0.60-   
Imports to sales %12.60-   
Exports (fob) Rs m162NA-   
Imports (cif) Rs m3,322NA-   
Fx inflow Rs m26844,118 0.6%   
Fx outflow Rs m3,92724,484 16.0%   
Net fx Rs m-3,65919,634 -18.6%   
CASH FLOW
From Operations Rs m2,51470,822 3.6%  
From Investments Rs m-800-42,216 1.9%  
From Financial Activity Rs m-803-22,854 3.5%  
Net Cashflow Rs m9126,107 14.9%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PANACEA BIOTECH COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS